Results 11 to 20 of about 273,925 (284)
PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
Frontiers in Oncology, 2021 Multiple myeloma (MM), the second most commonly diagnosed hematologic neoplasm, is the most significant clinical manifestation in a series of plasma cell (PC) dyscrasia.
Dong Wu +8 more
doaj +2 more sources
Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma [PDF]
Frontiers in Oncology, 2023 Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger +6 more
doaj +2 more sources
Protein-Functionalized Microgel for Multiple Myeloma Cells’ 3D Culture [PDF]
Biomedicines, 2022 Multiple myeloma is a hematologic neoplasm caused by an uncontrolled clonal proliferation of neoplastic plasma cells (nPCs) in the bone marrow. The development and survival of this disease is tightly related to the bone marrow environment.
Juan Carlos Marín-Payá +5 more
doaj +2 more sources
The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway. [PDF]
PLoS ONE, 2014 AIM: To investigate the inhibitory effect of pseudolaric acid B on subcutaneous xenografts of human gastric adenocarcinoma and the underlying molecular mechanisms involved in its multidrug resistance.
Qian Sun, Yan Li
doaj +2 more sources
PLoS ONE, 2013 Multiple myeloma (MM), the second most common hematopoietic malignancy, remains an incurable plasma cell (PC) neoplasm. While the proteasome inhibitor, bortezomib (Bz) has increased patient survival, resistance represents a major treatment obstacle as ...
Holly A F Stessman +5 more
doaj +2 more sources
Indian Journal of Pathology and Microbiology, 2013 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj +2 more sources
Venetoclax in the Therapeutic Strategy for BPDCN Management
eJHaemBackground Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Margaux Poussard +15 more
doaj +2 more sources
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
, 2021 Multiple myeloma is a malignant plasma cell neoplasm that remains incurable and is ultimately fatal when patients acquire multi-drug resistance. Thus, advancing our understanding of the mechanisms behind drug resistance in multi-relapsed patients is ...
Lorraine N. Davis, Daniel W. Sherbenou
core +1 more source
Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review) [PDF]
, 2016 Multiple myeloma (MM) is a mature B cell neoplasm that results in multi-organ failure. The median age of onset, diverse clinical manifestations, heterogeneous survival rate, clonal evolution, intrinsic and acquired drug resistance have impact on the ...
SABNA RAJEEV KRISHNAN +9 more
core +2 more sources
Synthesis and Antitumor Activity of a GSH Inert Bisphosphonate Platinum (II) Complex
Journal of Chemistry, 2022 Osteosarcoma is a highly aggressive neoplasm. Traditional platinum chemotherapeutic agents for osteosarcoma inevitably have acquired drug resistance and serious side effects, which have limited their utility.
Lu Ma +7 more
doaj +1 more source